Prebiotics may beneficially modulate innate immunity to promote immune homeostasis via both direct and indirect mechanisms. B-galacto-oligosaccharide (B-GOS) prebiotic supplementation beneficially influences markers of sub-clinical inflammation in humans (1) . The effect of B-GOS in active colonic inflammation has not previously been investigated. This study aimed to investigate the effect of 6-weeks B-GOS supplementation (containing active dose of 2.8 g/d β-GOS (Bimuno, Clasado, UK)) on clinical outcomes and faecal markers of inflammation, microbiota and microbial metabolites in patients with active ulcerative colitis (UC).
